Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Australian Kalydeco decision 'deferred,' patients will fight but need a champion

This article was originally published in Scrip

Executive Summary

Cystic fibrosis patients in Australia have lost round one in their battle to get affordable access to Vertex's Kalydeco, after the government-appointed body in charge of granting treatments for reimbursement deferred making a decision on the drug because it is priced too high. Patients in Australia who are eligible for the drug, which is used to treat CF sufferers with the G551D gene, say they feel they have no one "championing" their fight.

You may also be interested in...



Cystic Fibrosis: Successes, Opportunities And Challenges

What is next for the treatment of cystic fibrosis, a rare disease market that has boomed in recent years on the back of new drug approvals with hefty price tags? Pipelines are full, but securing reimbursement is a challenge.

Accessing Venture Debt From The EIB

Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.

In Vivo's 2024 Rising Leaders At A Glance

Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

SC022571

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel